Press releases

11/03/2025 - 18:00

SMAIO adds a new high-profile member to its scientific advisory board in the United States
10/22/2025 - 07:00

SMAIO signs a new distribution agreement for its open platform KEOPS-4ME with Orthofix in the U.S.
10/14/2025 - 17:45

SMAIO announces strong first-half 2025 results and robust growth in business activity in the third quarter of 2025
09/24/2025 - 19:00

First major distribution agreement for the KEOPS-4ME open platform with Highridge Medical in the U.S.
07/16/2025 - 17:45

SMAIO announces significant sales increase in H1 2025
05/12/2025 - 17:45

SMAIO announces the finalization of a €2.5 million fund-raising, consisting of a €1.5 million capital increase and a €1 million convertible bond issue
04/15/2025 - 17:45

SMAIO announces consolidated results for 2024 and record sales performance in Q1 2025
04/15/2025 - 17:45

SMAIO announces a €2.5 million fund-raising, consisting of a €1.5 million capital increase and a €1 million convertible bond issue
02/28/2025 - 18:00

SMAIO adds a new high-profile member to its scientific advisory board in the United States
01/27/2025 - 18:00

SMAIO provides update on its partnership with NuVasive and confirms its strategic focus on the U.S. market
01/21/2025 - 18:32

2024 annual sales at €5.5 million
01/06/2025 - 17:45

2025 financial calendar
10/15/2024 - 18:00

First-half 2024 results & creation of a US scientific advisory board
07/16/2024 - 18:00

First-half 2024 sales
04/16/2024 - 18:00

2023 annual results
01/23/2024 - 18:00

2023 sales up +120% to €5.4 million
11/21/2023 - 18:00

Success of a new educational program in the United States
11/09/2023 - 17:45

2024 Financial calendar
10/18/2023 - 18:00

First-half 2023 results
07/18/2023 - 17:45

First-half 2023 sales up +203% to €4.0 million
06/29/2023 - 18:00

SMAIO obtains €2.5m in non-dilutive financing
06/08/2023 - 07:00

SMAIO receives FDA 510(k) clearance for customized surgery planning software co-developed with NuVasive
04/11/2023 - 18:00

2022 full-year results
01/17/2023 - 18:00

2022 annual sales up +15% to €2.4 million
01/12/2023 - 17:45

2023 financial calendar
11/17/2022 - 18:00

SMAIO: success of the first educational program in the United States, the world’s largest spine market
10/25/2022 - 18:00

SMAIO announces the success of its first European educational programs
09/27/2022 - 18:00

First-half 2022 results
07/12/2022 - 18:00

First-half 2022 sales up +28% to €1.3 million
06/15/2022 - 18:00

SMAIO receives FDA 510(k) clearance for “K-rod”, its patient-specific union rod
06/08/2022 - 18:00

TP ICAP Midcap initiates coverage of SMAIO with a “Buy” recommendation
06/02/2022 - 18:00

SMAIO receives FDA 510(k) clearance for its Balance Analyzer 3D surgery planning software
04/29/2022 - 18:00

SMAIO, pioneer of a holistic approach to spinal surgery, announces its 2021 annual results and confirms its 2022 outlook
04/01/2022 - 18:00

Success of its IPO
03/23/2022 - 21:00

Launching of its IPO on the Euronext Growth® market in Paris

Press releases

SMAIO adds a new high-profile member to its scientific advisory board in the United States

SMAIO signs a new distribution agreement for its open platform KEOPS-4ME with Orthofix in the U.S.

SMAIO announces strong first-half 2025 results and robust growth in business activity in the third quarter of 2025

First major distribution agreement for the KEOPS-4ME open platform with Highridge Medical in the U.S.

SMAIO announces significant sales increase in H1 2025

SMAIO announces the finalization of a €2.5 million fund-raising, consisting of a €1.5 million capital increase and a €1 million convertible bond issue

SMAIO announces consolidated results for 2024 and record sales performance in Q1 2025

SMAIO announces a €2.5 million fund-raising, consisting of a €1.5 million capital increase and a €1 million convertible bond issue

SMAIO adds a new high-profile member to its scientific advisory board in the United States

SMAIO provides update on its partnership with NuVasive and confirms its strategic focus on the U.S. market

2024 annual sales at €5.5 million

2025 financial calendar

First-half 2024 results & creation of a US scientific advisory board

First-half 2024 sales

2023 annual results

2023 sales up +120% to €5.4 million

Success of a new educational program in the United States

2024 Financial calendar

First-half 2023 results

First-half 2023 sales up +203% to €4.0 million

SMAIO obtains €2.5m in non-dilutive financing

SMAIO receives FDA 510(k) clearance for customized surgery planning software co-developed with NuVasive

2022 full-year results

2022 annual sales up +15% to €2.4 million

2023 financial calendar

SMAIO: success of the first educational program in the United States, the world’s largest spine market

SMAIO announces the success of its first European educational programs

First-half 2022 results

First-half 2022 sales up +28% to €1.3 million

SMAIO receives FDA 510(k) clearance for “K-rod”, its patient-specific union rod

TP ICAP Midcap initiates coverage of SMAIO with a “Buy” recommendation

SMAIO receives FDA 510(k) clearance for its Balance Analyzer 3D surgery planning software

SMAIO, pioneer of a holistic approach to spinal surgery, announces its 2021 annual results and confirms its 2022 outlook

Success of its IPO

Launching of its IPO on the Euronext Growth® market in Paris